Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,051-1,100 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__178_C4,2 | Lung | Primary cancer | 3,234 | Tumor/Malignant | 47.2% | 0.90 | 0.35 |
| NSCLC_38242124__IMC__178_C4,3 | Lung | Primary cancer | 841 | Stromal | 59.5% | 0.91 | 0.24 |
| NSCLC_38242124__IMC__178_C4,4 | Lung | Primary cancer | 3,588 | Immune | 39.3% | 0.84 | 0.31 |
| NSCLC_38242124__IMC__178_C4,5 | Lung | Primary cancer | 1,781 | Tumor/Malignant | 34.9% | 0.90 | 0.31 |
| NSCLC_38242124__IMC__178_C4,6 | Lung | Primary cancer | 2,389 | Stromal | 27.6% | 0.76 | 0.51 |
| NSCLC_38242124__IMC__178_C4,7 | Lung | Primary cancer | 1,156 | Stromal | 31.4% | 0.82 | 0.53 |
| NSCLC_38242124__IMC__178_C4,8 | Lung | Primary cancer | 2,624 | Tumor/Malignant | 52.1% | 1.00 | 0.04 |
| NSCLC_38242124__IMC__178_C4,9 | Lung | Primary cancer | 3,608 | Stromal | 26.9% | 0.45 | 0.91 |
| NSCLC_38242124__IMC__178_C5,1 | Lung | Primary cancer | 2,844 | Stromal | 30.1% | 0.72 | 0.60 |
| NSCLC_38242124__IMC__178_C5,10 | Lung | Primary cancer | 3,113 | Tumor/Malignant | 49.0% | 0.96 | 0.14 |
| NSCLC_38242124__IMC__178_C5,11 | Lung | Primary cancer | 4,483 | Stromal | 46.0% | 0.75 | 0.51 |
| NSCLC_38242124__IMC__178_C5,12 | Lung | Primary cancer | 5 | Not ready | NA | NA | NA |
| NSCLC_38242124__IMC__178_C5,13 | Lung | Primary cancer | 1,856 | Tumor/Malignant | 33.4% | 0.83 | 0.47 |
| NSCLC_38242124__IMC__178_C5,16 | Lung | Primary cancer | 1,984 | Immune | 95.1% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__178_C5,17 | Lung | Primary cancer | 1,276 | Other | 48.4% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__178_C5,2 | Lung | Primary cancer | 2,065 | Tumor/Malignant | 43.7% | 0.89 | 0.28 |
| NSCLC_38242124__IMC__178_C5,3 | Lung | Primary cancer | 2,893 | Stromal | 30.1% | 0.85 | 0.45 |
| NSCLC_38242124__IMC__178_C5,4 | Lung | Primary cancer | 3,222 | Tumor/Malignant | 33.2% | 0.95 | 0.19 |
| NSCLC_38242124__IMC__178_C5,7 | Lung | Primary cancer | 1,165 | Tumor/Malignant | 28.4% | 0.72 | 0.54 |
| NSCLC_38242124__IMC__178_C5,8 | Lung | Primary cancer | 2,625 | Tumor/Malignant | 75.4% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__178_C5,9 | Lung | Primary cancer | 84 | Tumor/Malignant | 69.0% | 0.74 | 0.45 |
| NSCLC_38242124__IMC__178_C6,1 | Lung | Primary cancer | 3,188 | Immune | 35.4% | 0.94 | 0.19 |
| NSCLC_38242124__IMC__178_C6,10 | Lung | Primary cancer | 3,397 | Stromal | 39.9% | 0.88 | 0.31 |
| NSCLC_38242124__IMC__178_C6,13 | Lung | Primary cancer | 2,797 | Tumor/Malignant | 55.0% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__178_C6,15 | Lung | Primary cancer | 2,501 | Tumor/Malignant | 26.8% | 0.49 | 0.93 |
| NSCLC_38242124__IMC__178_C6,16 | Lung | Primary cancer | 6,911 | Immune | 86.2% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__178_C6,17 | Lung | Primary cancer | 884 | Tumor/Malignant | 63.1% | 1.00 | 0.01 |
| NSCLC_38242124__IMC__178_C6,2 | Lung | Primary cancer | 3,041 | Tumor/Malignant | 76.6% | 0.97 | 0.08 |
| NSCLC_38242124__IMC__178_C6,4 | Lung | Primary cancer | 3,154 | Immune | 28.3% | 0.46 | 0.88 |
| NSCLC_38242124__IMC__178_C6,5 | Lung | Primary cancer | 3,116 | Tumor/Malignant | 34.5% | 0.90 | 0.34 |
| NSCLC_38242124__IMC__178_C6,6 | Lung | Primary cancer | 5,941 | Immune | 51.1% | 0.96 | 0.11 |
| NSCLC_38242124__IMC__178_C7,1 | Lung | Primary cancer | 2,065 | Stromal | 47.2% | 0.99 | 0.08 |
| NSCLC_38242124__IMC__178_C7,10 | Lung | Primary cancer | 4,343 | Tumor/Malignant | 75.6% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__178_C7,11 | Lung | Primary cancer | 3,648 | Other | 22.0% | 0.34 | 0.99 |
| NSCLC_38242124__IMC__178_C7,12 | Lung | Primary cancer | 2,028 | Stromal | 29.2% | 0.85 | 0.46 |
| NSCLC_38242124__IMC__178_C7,13 | Lung | Primary cancer | 4,135 | Tumor/Malignant | 43.7% | 0.90 | 0.31 |
| NSCLC_38242124__IMC__178_C7,15 | Lung | Primary cancer | 434 | Stromal | 50.5% | 0.84 | 0.39 |
| NSCLC_38242124__IMC__178_C7,16 | Lung | Primary cancer | 6,979 | Immune | 84.2% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__178_C7,17 | Lung | Primary cancer | 3,366 | Tumor/Malignant | 77.0% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__178_C7,3 | Lung | Primary cancer | 1,170 | Stromal | 43.1% | 0.55 | 0.85 |
| NSCLC_38242124__IMC__178_C7,5 | Lung | Primary cancer | 2,906 | Tumor/Malignant | 39.7% | 0.90 | 0.33 |
| NSCLC_38242124__IMC__178_C7,6 | Lung | Primary cancer | 5,969 | Tumor/Malignant | 54.0% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__178_C7,7 | Lung | Primary cancer | 4,149 | Tumor/Malignant | 29.7% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__178_C7,8 | Lung | Primary cancer | 4,592 | Tumor/Malignant | 53.0% | 0.94 | 0.22 |
| NSCLC_38242124__IMC__178_C7,9 | Lung | Primary cancer | 4,120 | Tumor/Malignant | 41.7% | 0.93 | 0.29 |
| NSCLC_38242124__IMC__178_C8,1 | Lung | Primary cancer | 3,436 | Immune | 23.9% | 0.83 | 0.47 |
| NSCLC_38242124__IMC__178_C8,10 | Lung | Primary cancer | 3,751 | Tumor/Malignant | 62.2% | 0.97 | 0.10 |
| NSCLC_38242124__IMC__178_C8,12 | Lung | Primary cancer | 1,093 | Stromal | 47.7% | 0.86 | 0.39 |
| NSCLC_38242124__IMC__178_C8,13 | Lung | Primary cancer | 3,461 | Tumor/Malignant | 42.9% | 0.73 | 0.61 |
| NSCLC_38242124__IMC__178_C8,14 | Lung | Primary cancer | 1,292 | Immune | 31.0% | 0.88 | 0.33 |